Blue Trust Inc. Has $56,000 Stock Holdings in Elanco Animal Health Incorporated $ELAN

Blue Trust Inc. decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 37.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,936 shares of the company’s stock after selling 2,402 shares during the quarter. Blue Trust Inc.’s holdings in Elanco Animal Health were worth $56,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. HighTower Advisors LLC lifted its holdings in Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock worth $131,000 after buying an additional 810 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Elanco Animal Health by 8.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,516 shares of the company’s stock worth $169,000 after buying an additional 944 shares in the last quarter. Graypoint LLC lifted its holdings in Elanco Animal Health by 4.9% during the 1st quarter. Graypoint LLC now owns 26,845 shares of the company’s stock worth $282,000 after buying an additional 1,256 shares in the last quarter. Commerce Bank lifted its holdings in Elanco Animal Health by 3.7% during the 1st quarter. Commerce Bank now owns 35,321 shares of the company’s stock worth $371,000 after buying an additional 1,256 shares in the last quarter. Finally, Probity Advisors Inc. lifted its holdings in Elanco Animal Health by 10.0% during the 1st quarter. Probity Advisors Inc. now owns 14,520 shares of the company’s stock worth $152,000 after buying an additional 1,314 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ELAN. Stifel Nicolaus increased their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. William Blair raised Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Wall Street Zen raised Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target on the stock in a research note on Thursday, July 17th. Finally, JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.14.

Elanco Animal Health Price Performance

ELAN opened at $21.42 on Friday. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $21.76. The company has a fifty day simple moving average of $18.90 and a 200 day simple moving average of $14.78. The stock has a market cap of $10.64 billion, a P/E ratio of 24.91, a P/E/G ratio of 3.93 and a beta of 1.65.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.